# Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses

Source: [nature.com](https://www.nature.com/articles/s41467-026-79192-3) · 2026-11-15 · Life
Page: https://themorning.science/story/cytotoxic-drugs-and-bispecific-t-cell-engagers-synergize-to-rewire-host-immunity-74abd16e35f358c5
Kind: research · Impact: medium

## In brief

- A study published in Nature Communications on 15 November 2026 reports that cytotoxic drugs and bispecific T cell engagers act synergistically.
- The authors report that the combination rewires host immunity and elicits polyclonal antitumor T cell responses.
- The work focuses on TAA×CD28 costimulatory bispecific antibodies, which crosslink CD28 on T cells to a tumor-associated antigen to provide tumor-targeted costimulation.

## Why it matters

It suggests that combining established cytotoxic drugs with bispecific T cell engagers could broaden antitumour T cell responses, which may inform how cancer immunotherapies are combined.

## Timeline

- 2026-11-15: Study published online in Nature Communications

## Coverage

- [Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses](https://www.nature.com/articles/s41467-026-79192-3) — nature.com, 2026-11-15

Tags: cancer immunotherapy, t cells, bispecific antibodies, cytotoxic drugs, costimulation

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science